Ubs Group Ag Aptinyx Inc. Transaction History

Ubs Group Ag

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$0.23 - $0.34 $6,194 - $9,157	-26,933 Reduced 98.31%	462 $0
Q3 2022 Nov 10, 2022	BUY	$0.35 - $0.72 $9,588 - $19,724	27,395 New	27,395 $10,000
Q4 2021 Feb 14, 2022	SELL	$2.11 - $3.0 $4,036 - $5,739	-1,913 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.21 - $2.89 $1,124 - $1,471	509 Added 36.25%	1,913 $4,000
Q2 2021 Aug 13, 2021	SELL	$2.39 - $3.5 $18,584 - $27,216	-7,776 Reduced 84.71%	1,404 $4,000
Q1 2021 May 12, 2021	BUY	$2.86 - $4.33 $237 - $359	83 Added 0.91%	9,180 $28,000
Q4 2020 Feb 11, 2021	BUY	$2.93 - $4.3 $23,428 - $34,382	7,996 Added 726.25%	9,097 $31,000
Q3 2020 Nov 12, 2020	SELL	$3.05 - $4.99 $20,880 - $34,161	-6,846 Reduced 86.15%	1,101 $4,000
Q2 2020 Jul 31, 2020	BUY	$1.99 - $4.4 $15,217 - $33,646	7,647 Added 2549.0%	7,947 $33,000
Q4 2019 Feb 14, 2020	SELL	$2.84 - $4.25 $5,563 - $8,325	-1,959 Reduced 86.72%	300 $1,000
Q3 2019 Nov 14, 2019	BUY	$3.0 - $4.08 $3,477 - $4,728	1,159 Added 105.36%	2,259 $8,000
Q1 2019 May 14, 2019	BUY	$3.99 - $19.33 $399 - $1,932	100 Added 10.0%	1,100 $4,000
Q4 2018 Feb 14, 2019	SELL	$16.15 - $28.93 $23,304 - $41,745	-1,443 Reduced 59.07%	1,000 $17,000
Q3 2018 Nov 14, 2018	BUY	$20.21 - $31.85 $49,373 - $77,809	2,443 New	2,443 $70,000

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.